Evidence map›Paper›PMID 26768249›Full record

ArticleThe Journal of infectious diseases2016

Within-Host Heterogeneity of Mycobacterium tuberculosis Infection Is Associated With Poor Early Treatment Response: A Prospective Cohort Study.

Ted Cohen, Leonid Chindelevitch, Reshma Misra, Maria E Kempner, Jerome Galea, Prashini Moodley, Douglas Wilson

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Mixed infections and heteroresistance ofEmerging microbes & infections · 2025
    Article
  7. Review
  8. Article
  9. Dissecting rifampicin heteroresistance inJournal of medical microbiology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. InvestigatingMicrobiology spectrum · 2023
    Article
  17. Article
  18. Ultrasensitive Detection of Multidrug-ResistantInternational journal of molecular sciences · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Ted CohenDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut.
Leonid ChindelevitchDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut.
Reshma MisraInfection Prevention and Control, University of KwaZulu-Natal, Durban.
Maria E KempnerBrigham and Women's Hospital.
Jerome GaleaPartners in Health, Boston, Massachusetts.
Prashini MoodleyInfection Prevention and Control, University of KwaZulu-Natal, Durban.
Douglas WilsonDepartment of Internal Medicine, Edendale Hospital, University of KwaZulu-Natal, Pietermaritzburg, South Africa.

Funding

Understanding and controlling antibiotic resistanceU54GM088558 · NIGMS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LIPSITCH, MARC · 2009 to 2018
$26.4M
Prevalence, risk factors and consequences of complex M. Tuberculosis infectionsDP2OD006663 · OD · BRIGHAM AND WOMEN'S HOSPITAL · PI COHEN, THEODORE H · 2010 to 2010
$2.7M
NIGMS NIH HHS U54 GM088558NIH HHS DP2 OD006663
6 · The paper itself

Abstract

The clinical management of tuberculosis is a major challenge in southern Africa. The prevalence of within-host genetically heterogeneous Mycobacterium tuberculosis infection and its effect on treatment response are not well understood. We enrolled 500 patients with tuberculosis in KwaZulu-Natal and followed them through 2 months of treatment. Using mycobacterial interspersed repetitive units-variable number of tandem repeats genotyping to identify mycobacterial heterogeneity, we report the prevalence and evaluate the association of heterogeneity with treatment response. Upon initiation of treatment, 21.1% of participants harbored a heterogeneous M. tuberculosis infection; such heterogeneity was independently associated with a nearly 2-fold higher odds of persistent culture positivity after 2 months of treatment (adjusted odds ratio, 1.90; 95% confidence interval, 1.03-3.50).

Indexed as

Genetic HeterogeneityAdultAntitubercular AgentsCohort StudiesFemaleFollow-Up StudiesHIV InfectionsHumansMaleMycobacterium tuberculosisProspective StudiesSouth AfricaSputumTime-to-TreatmentTuberculosis, PulmonaryAntitubercular AgentscoinfectionHIV/TBmixed infectiontuberculosiswithin-host heterogeneity

Identifiers

PMID26768249
PMCPMC4857469

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.